Risk factors for sustained virological non-suppression among children and adolescents living with HIV in Zimbabwe and Malawi: a secondary data analysis

Christi Jackson, Andrea M Rehman, Grace McHugh, Carmen Gonzalez-Martinez, Lucky G Ngwira, Tsitsi Bandason, Hilda Mujuru, Jon O Odland, Elizabeth L Corbett, Rashida A Ferrand, Victoria Simms, Christi Jackson, Andrea M Rehman, Grace McHugh, Carmen Gonzalez-Martinez, Lucky G Ngwira, Tsitsi Bandason, Hilda Mujuru, Jon O Odland, Elizabeth L Corbett, Rashida A Ferrand, Victoria Simms

Abstract

Background: We investigated risk factors for sustained virological non-suppression (viral load ≥ 1000 copies/ml on two tests 48 weeks apart) among children and adolescents accessing HIV care in public sector clinics in Harare, Zimbabwe and Blantyre, Malawi.

Methods: Participants were enrolled between 2016 and 2019, were aged 6-19 years, living with HIV, had chronic lung disease (FEV z-score < -1) and had taken antiretroviral therapy (ART) for at least six months. We used multivariate logistic regression to identify risk factors for virological non-suppression after 48 weeks, among participants who were non-suppressed at enrolment.

Results: At enrolment 258 participants (64.6%) were on first-line ART and 152/347 (43.8%) had virological non-suppression. After 48 weeks 114/313 (36.4%) were non-suppressed. Participants non-suppressed at baseline had almost ten times higher odds of non-suppression at follow-up (OR = 9.9, 95%CI 5.3-18.4, p < 0.001). Of those who were non-suppressed at enrolment, 87/136 (64.0%) were still non-suppressed at 48 weeks. Among this group non-suppression at 48 weeks was associated with not switching ART regimen (adjusted OR = 5.55; 95%CI 1.41-21.83); p = 0.014) and with older age. Twelve participants switched regimen in Zimbabwe and none in Malawi.

Conclusions: Viral non-suppression was high among this group and many with high viral load were not switched to a new regimen, resulting in continued non-suppression after 48 weeks. Further research could determine whether improved adherence counselling and training clinicians on regimen switches can improve viral suppression rates in this population.

Trial registration: Secondary cohort analysis of data from BREATHE trial (Clinicaltrials.gov NCT02426112 ).

Keywords: Adolescent; Antiretroviral therapy; Chronic lung disease; HIV viral load; Resistance; Viral non-suppression.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

References

    1. Ministry of Health and Child Care. Harare: 2019. Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) 2015–2016. Final Report.
    1. Ministry of Health and Child Care. Guidelines for antiretroviral therapy for the prevention and treatment of HIV in Zimbabwe. Harare: Zimbabwe Ministry of Health and Child Care; 2016
    1. Malawi Ministry of Health . Malawi guidelines for clinical management of HIV in children and adults. 3. Lilongwe: Malawi Ministry of Health; 2016.
    1. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organisation; 2016
    1. Madec Y, Leroy S, Rey-Cuille MA, Huber F, Calmy A. Persistent difficulties in switching to second-line ART in sub-saharan Africa–a systematic review and meta-analysis. PLoS One. 2013;8(12):e82724. doi: 10.1371/journal.pone.0082724.
    1. Harries AD, Zachariah R, van Oosterhout JJ, Reid SD, Hosseinipour MC, Arendt V, Chirwa Z, Jahn A, Schouten EJ, Kamoto K. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis. 2010;10(1):60–65. doi: 10.1016/S1473-3099(09)70321-4.
    1. Gonzalez-Martinez C, Kranzer K, McHugh G, Corbett EL, Mujuru H, Nicol MP, Rowland-Jones S, Rehman AM, Gutteberg TJ, Flaegstad T, et al. Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trial. Trials. 2017;18(1):622. doi: 10.1186/s13063-017-2344-2.
    1. McHugh G, Rehman AM, Simms V, Gonzalez-Martinez C, Bandason T, Dauya E, Moyo B, Mujuru H, Rylance J, Sovershaeva E, et al. Chronic lung disease in children and adolescents with HIV: a case-control study. Trop Med Int Health. 2020;25(5):590–599. doi: 10.1111/tmi.13375.
    1. Ferrand RA, McHugh G, Rehman AM, Mujuru H, Simms V, Majonga ED, Nicol MP, Flaegstad T, Gutteberg TJ, Gonzalez-Martinez C, et al. Effect of once-weekly azithromycin vs placebo in children with HIV-associated chronic lung disease: the BREATHE randomized clinical trial. JAMA Netw Open. 2020;3(12):e2028484. doi: 10.1001/jamanetworkopen.2020.28484.
    1. Rehman AM, Simms V, McHugh G, Mujuru H, Ngwira LG, Semphere R, Moyo B, Bandason T, Odland J, Ferrand R: Adherence to additional medication for management of HIV-associated comorbidities among older children and adolescents taking antiretroviral therapy. PLOS One. 2021, (in press).
    1. UNAIDS . UNAIDS data 2019. 2019.
    1. Malawi Ministry of Health . Malawi Population-Based HIV Impact Assessment (MPHIA) 2015–2016: Final Report. Lilongwe: Ministry of Health; 2018.
    1. Rylance J, McHugh G, Metcalfe J, Mujuru H, Nathoo K, Wilmore S, Rowland-Jones S, Majonga E, Kranzer K, Ferrand RA. Chronic lung disease in HIV-infected children established on antiretroviral therapy. AIDS. 2016;30(18):2795–2803. doi: 10.1097/QAD.0000000000001249.
    1. Barker AF. Bronchiectasis. N Engl J Med. 2002;346(18):1383–1393. doi: 10.1056/NEJMra012519.
    1. Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review. AIDS Care. 2015;27(7):805–816. doi: 10.1080/09540121.2015.1011073.
    1. Taddeo D, Egedy M, Frappier JY. Adherence to treatment in adolescents. Paediatr Child Health. 2008;13(1):19–24. doi: 10.1093/pch/13.1.19.
    1. Vandenhende MA, Ingle S, May M, Chene G, Zangerle R, Van Sighem A, Gill MJ, Schwarze-Zander C, Hernandez-Novoa B, Antiretroviral Therapy Cohort C et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015;29(3):373–383. doi: 10.1097/QAD.0000000000000544.
    1. World Health Organisation . Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organisation; 2021.
    1. Makadzange AT, Higgins-Biddle M, Chimukangara B, Birri R, Gordon M, Mahlanza T, McHugh G, van Dijk JH, Bwakura-Dangarembizi M, Ndung'u T, et al. Clinical, virologic, immunologic outcomes and emerging HIV drug resistance patterns in children and adolescents in public ART care in Zimbabwe. PLoS One. 2015;10(12):e0144057. doi: 10.1371/journal.pone.0144057.
    1. Kouamou V, Varyani B, Shamu T, Mapangisana T, Chimbetete C, Mudzviti T, Manasa J, Katzenstein D. Drug resistance among adolescents and young adults with virologic failure of first-line antiretroviral therapy and response to second-line treatment. AIDS Res Hum Retroviruses. 2020;36(7):566–573. doi: 10.1089/aid.2019.0232.
    1. Kyaw NT, Harries AD, Kumar AM, Oo MM, Kyaw KW, Win T, Aung TK, Min AC, Oo HN. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005–2015. PLoS One. 2017;12(2):e0171780. doi: 10.1371/journal.pone.0171780.
    1. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, Bangsberg DR, Yiannoutsos CT, Deeks SG, Martin JN. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS. 2014;28(14):2097–2107. doi: 10.1097/QAD.0000000000000349.
    1. Bernheimer JM, Patten G, Makeleni T, Mantangana N, Dumile N, Goemaere E, Cox V. Paediatric HIV treatment failure: a silent epidemic. J Int AIDS Soc. 2015;18:20090. doi: 10.7448/IAS.18.1.20090.
    1. Porter JD, Porter MNM, du Plessis M. Not yet 90–90-90: A quality improvement approach to human immunodeficiency virus viral suppression in paediatric patients in the rural Eastern Cape, South Africa. S Afr J Fam Pract. 2020;62(1):a5169.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner